Seqens is an integrated global leader in pharmaceutical synthesis and specialty ingredients with 24 manufacturing sites and 7 R&D centers in Europe, North America and Asia.
Location: France, Auvergne-Rhone-Alpes, Écully
Investors 3
| Date | Name | Website |
| - | Merieux De... | merieux-pa... |
| - | Ardian | ardian.com |
| - | Eurazeo | eurazeo.co... |
Mentions in press and media 3
| Date | Title | Description |
| 17.08.2026 | Lucintel Forecasts the Global Salicylic Acid Market to reach $230 million by 2035 | According to a market report by Lucintel, the future of the global salicylic acid market looks promising with opportunities in the pharmaceutical, cosmetics & personal care, and food & beverage markets. The global salicylic acid mar... |
| 17.12.2021 | Change in SEQENS' Shareholding Structure – SEQENS Is Now Stronger, More Focused and Positioned as One of the World's Leading Players in Pharmaceutical Solutions and Specialty Ingredients | SEQENS is pleased to announce that, on December 16, 2021, funds advised by SK Capital have become the majority shareholder of the group. Two new long-term institutional investors, Bpifrance and Nov Santé are taking part in the transaction a... |
| 27.08.2021 | Five years after its entry into the capital of SEQENS, Eurazeo announces that it has entered into exclusive discussions to sell its stake in SEQENS. The deal is expected to close by the end of 2021. | PRESS RELEASE | ECULLY, FRANCE – August 26th, 2021 Eurazeo today announced that it has entered into exclusive discussions to sell its stake in SEQENS to funds advised by SK Capital Partners (“SK Capital”) and to the company’s existing Fren... |